Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
Northeast · Massachusetts
Local context for Wegovy, Ozempic, Mounjaro, and Zepbound in Boston (660,000 residents, 4,900,000 metro). MassHealth covers T2D GLP-1s with prior auth; Mass General Brigham runs nationally ranked obesity-medicine programs.
Availability and prices vary by pharmacy and date. We do not maintain real-time per-pharmacy stock data. Confirm with pharmacies directly.
Wegovy
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for chronic weight management in adults and adolescents.
Wegovy in Boston →
Ozempic
semaglutide · Novo Nordisk
Once-weekly semaglutide injection FDA-approved for adults with type 2 diabetes.
Ozempic in Boston →
Mounjaro
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for adults with type 2 diabetes.
Mounjaro in Boston →
Zepbound
tirzepatide · Eli Lilly
Once-weekly tirzepatide injection FDA-approved for chronic weight management and obstructive sleep apnea.
Zepbound in Boston →
Boston is a northeast-region city with a population of 660,000 (4,900,000 in the broader metropolitan area). Massachusetts expanded Medicaid under the Affordable Care Act, which means low-income adults can typically qualify for GLP-1 coverage for type 2 diabetes if the state Medicaid program lists the drug.
Statewide, notable health systems include Mass General Brigham, Beth Israel Deaconess, Boston Children's.
Massachusetts's Medicaid program is MassHealth. Coverage rules for GLP-1 medications vary by drug and indication; see our pricing by state map and payer-coverage guides for details.
Cities of similar size with comparable healthcare markets.